Clinical trials: Cardiovascular (CV) Risk
Cardiovascular (CV) Risk
Effect of Eliminating Red Meat Consumption on the Cardiovascular System
The objective of this clinical trial is to evaluate, in clinically healthy young omnivores, whether excluding red and processed meat from their diets for four weeks results in: measurable changes in arterial structure and…
- Trial name
- ERRM (NCT07205237)
- Testing
- Diet without Red and Processed Meat
- Where
- Portugal
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Maria Clara Rocha
Type 2 Diabetes, Cardiovascular Complication
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble…
- Trial name
- Diabetes-CV (NCT06902857)
- Where
- Italy
- Volunteers
- 964 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Cardiovascular (CV) Risk, Heart Attack Patients
Health Behaviour and Readiness to Change After Myocardial Infarction: A Cross-sectional Survey
This study investigates health behaviour and readiness for lifestyle change in patients who recently had a heart attack (myocardical infarction) treated with stenting (PTCA).
- Trial name
- HerzAktiv (NCT07785921)
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Kliniken Essen-Mitte
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current…
- Trial name
- NCT02666664
- Testing
- ETC-1002
- Where
- 104 sites in United States, Canada and 4 more
- Volunteers
- 2,230 people
- Sponsor
- Esperion Therapeutics, Inc.
Cardiovascular Risk, Cardiovascular Prevention
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
Cardiovascular (CV) disease is the #1 cause of premature mortality and substantial morbidity in the U.S. Despite clinical guidelines, most clinical interventions are implemented in people at relatively lower CV risk, and few…
- Trial name
- SDM4IP (NCT04450914)
- Testing
- CV Prevention Choice Tool, Implementation Facilitation Strategies
- Where
- 4 sites in United States
- Volunteers
- 112,127 people
- Sponsor
- Mayo Clinic
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death.
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
- Trial name
- NCT07223385
- Testing
- Cardio-Oncology Referral, Notification to PCP/General Cardiologist
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiovascular Diseases
Development of CV Risk Prediction Tools Based on AI and Fundus Imaging Technology Study (PERFECT)
This study aims to develop a cardiovascular disease (CVD) screening tool and cardiovascular risk prediction tool based on fundus imaging data with the method of artificial intelligence.
- Trial name
- PERFECT (NCT06181552)
- Testing
- fundus photograpgy, optical coherence tomography, optical coherence tomography angiography
- Volunteers
- 1,072 people, healthy volunteers welcome
- Sponsor
- China National Center for Cardiovascular Diseases
Cardiovascular Disease
Better Adherence to Therapeutic Lifestyle Change Efforts Trial
The purpose of this study is to determine whether knowledge of abnormal results from a noninvasive test for detection of subclinical atherosclerosis (carotid intima media thickness [CIMT]), in addition to knowledge of…
- Trial name
- BATTLE (NCT00458874)
- Testing
- CIMT results
- Where
- United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Cardiovascular (CV) Risk, Atheroscleroses
Exploring Sustainable Alternatives to Marine Oils With Echium and Ahiflower Oils
This randomized, single-blind, crossover clinical trial aims to evaluate Echium oil and Ahiflower® oil as sustainable, plant-based alternatives to marine oils for omega-3 supplementation.
- Conditions
- Cardiovascular (CV) Risk, Atheroscleroses, Inflamation, Omega 3 Fatty Acids
- Trial name
- NCT07289919
- Testing
- Echium oil, Ahiflower oil, EPA capsules
- Where
- Brazil
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
HIV/AIDS
Risk of CV Events With EFV vs. EFV-free Regimens
The purpose of this study is to determine whether there is an increased risk of cardiovascular events (CV) with regimens containing efavirenz (EFV) versus other regimens in patients with HIV.
- Trial name
- NCT02426866
- Testing
- Efavirenz
- Volunteers
- 29,612 people
- Sponsor
- Bristol-Myers Squibb
Autism, Adverse Childhood Experience
A Two-Part Intervention to Target Cardiovascular Health
Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals.
- Conditions
- Autism, Adverse Childhood Experience, Stress, Cardiovascular (CV) Risk
- Trial name
- NCT07673172
- Testing
- Lifestyle Medicine, Cognitive Behavioral Therapy (CBT), Lifestyle Medicine with CBT Group
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of California, Los Angeles
Coronary Artery Disease
Family Atherosclerosis Counseling and Testing Project
Family history of early atherosclerotic disease in a first-degree relative [(FDR) sibling, parent or child] is an important risk factor for coronary artery and/or vascular disease.
- Trial name
- NCT00387595
- Sponsor
- University of British Columbia
Cardiovascular (CV) Risk, Behavioral Changes
Growing Healthy Hearts
This proposal includes a prospective, parallel group, two-arm RCT with 264 adult-child dyads (adult age 18+, child ages 5-17 years) to examine the effectiveness of the Growing Healthy Hearts (GHH) intervention versus a wait list…
- Conditions
- Cardiovascular (CV) Risk, Behavioral Changes, Gardening, Cooking
- Trial name
- GHH (NCT07684027)
- Testing
- GHH Intervention
- Where
- United States
- Volunteers
- 264 people
- Sponsor
- Milton S. Hershey Medical Center
Cardiovascular (CV) Risk, Exercise
The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy
The goal of this study is to determine the effectiveness of a mobile exercise app in improving cardiovascular health and motivation to exercise in pregnant women who are healthy, in their 2nd trimester, between 18-45 years age…
- Trial name
- NCT07166822
- Testing
- Experimental group using BumptUp mobile exercise app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer